True Footage Inc v Automax AI Inc - Copyright

True Footage Inc. filed a civil copyright complaint against defendants Humza Ahmed, Automax AI Inc., and Automax AI (US) Inc. in the Northern District of California on April 22, 2026. The complaint was filed with the court accompanied by three exhibits and required a $405 filing fee. This marks the initiation of a federal civil action alleging copyright infringement.

NY Executive Order 60 Prohibits State Employees from Insider Trading in Prediction Markets

Governor Kathy Hochul has issued Executive Order 60 prohibiting state employees serving at the pleasure of the Governor and public authority members appointed by the Governor from using nonpublic information obtained in their official duties to profit or avoid loss from participation in prediction markets or similar services. The order covers exchange-traded platforms not licensed by the New York State Gaming Commission, including contracts contingent on elections, sporting events, individual actions or speech, and economic indicators. Violations may result in dismissal, other sanctions, or referral to law enforcement or the Commission on Ethics and Lobbying in Government.

Qu Biologics Inc. EP3137108A1 Anti-Microbial Immunomodulation

The European Patent Office published EP3137108A1 on April 15, 2026, titled 'ANTI-MICROBIAL IMMUNOMODULATION.' The patent application, filed by Qu Biologics Inc., names inventors Harold David Gunn, Salim Dhanji, and David W. Mullins. The invention is classified under IPC categories A61K 39/108, A61K 39/00, A61P 31/04, and A61P 31/12. Designation extends across all relevant European member states including DE, FR, GB, IT, NL, ES, PL, and 24 others.

Compositions for Treating Bone Diseases and Broken Bones, Brigham Young University, EP2755661A1

The EPO published patent application EP2755661A1 for Brigham Young University on April 15, 2026, covering compositions for treating bone diseases and broken bones. The application, classified under A61K 31/575 and related pharmaceutical classes, designates 35 European states including AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, HR, HU, IE, IT, LI, LT, LU, MC, NL, NO, PL, PT, RO, SE, SI, SK, and SM. Inventors are Carl Genberg and Paul B. Savage.

LEO Pharma A/S Pharmaceutical Spray Composition Patent EP2859886A1

The European Patent Office published patent application EP2859886A1 for LEO Pharma A/S covering a pharmaceutical spray composition. The application lists five inventors: Lind, Marianne; Rasmussen, Grit; Sonne, Mette Rydahl; Hansen, Jens; and Petersson, Karsten. The IPC classifications span A61K 9/12 (aerosol compositions), A61K 47/06 (organic compounds), A61K 47/10 (glycols), and A61K 9/00 (pharmaceutical preparations). The application designates 37 European states including major pharmaceutical markets such as Germany, France, the United Kingdom, and the Netherlands.

AbbVie Inc. - Methods for Treating HCV (EP3125889A1)

AbbVie Inc. filed European patent application EP3125889A1 for methods of treating Hepatitis C Virus (HCV) infection with pharmaceutical compositions classified under A61K 31/454, A61K 31/498, and A61K 31/7072. The European Patent Office published the application on April 15, 2026, establishing a priority date of October 16, 2015. The patent designates all European Patent Convention contracting states, covering AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Agios Crystalline Salt Forms of Quinolinesulfonamide - EP3972957A1

The European Patent Office published application EP3972957A1 on 15 April 2026, covering crystalline salt forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide. Agios Pharmaceuticals, Inc. is the applicant, with Lisa M. Grove listed as inventor. The application covers the pharmaceutical compound classified under C07D 215/36, A61P 7/06, and A61K 31/4709, with designated states spanning across European member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Redwood Bioscience Anti-HER2 Antibody-Maytansine Conjugate Patent Application EP3151830A1

The EPO published patent application EP3151830A1 by Redwood Bioscience, Inc. on April 15, 2026, covering anti-HER2 antibody-maytansine conjugates and methods of use for cancer treatment. The application names eight inventors and falls under IPC classifications A61K 47/68 and A61K 31/4045, with potential coverage across 34 European designated states including Germany, France, the United Kingdom, Italy, and Spain.

Daicel Corporation Osteoclast Differentiation Inhibitor Urolithin EP3756664A1

The European Patent Office published patent application EP3756664A1 for Daicel Corporation on April 15, 2026, covering osteoclast differentiation inhibitor compositions containing urolithin. The inventors are KOBATA Kenji, NAKATANI Sachie, and KUDOH Masatake. The application is classified under A61K 31/37 (phthalide compounds) with designations covering 32 European states including DE, FR, GB, IT, and NL.

Selective Reduction of Cysteine Residues in IL-17 Antibodies

The European Patent Office published patent application EP3237445A1 by Novartis AG, covering methods for the selective reduction of cysteine residues in IL-17 antibodies. The application names HEITZMANN, Markus and WINKLER, Johann as inventors, with international patent classification codes C07K 16/24 and A61K 39/395. This A1 publication includes the European search report and designates all EU member states plus Switzerland, Norway, and other European Economic Area countries.

Genentech Patent - Quaternary Amine ADC Compounds, Apr 2026

The EPO published patent application EP3226909A1 for Genentech, Inc., covering quaternary amine compounds and antibody-drug conjugates (ADCs) thereof. The application, filed under IPC classifications A61K 47/68, A61P 35/00, and multiple C07D chemical classes, designates all current EPO contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR. Named inventors are John A. FLYGARE, Thomas PILLOW, and Leanna STABEN.

Strike Bio RNAi Cancer Treatment Patent Application EP3134528A1

The European Patent Office published patent application EP3134528A1 titled 'Multiple Targeted RNAi for the Treatment of Cancers' on April 15, 2026. The applicants are Strike Bio, Inc. and Baylor College of Medicine, both based in the United States. The invention covers RNAi-based therapeutics targeting multiple genes for cancer treatment, with the application designating 34 European member states including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands.

Porous Particles Patent, Lucideon Limited, Apr 2026

The EPO published patent application EP3236946A1 for porous particles by Lucideon Limited on April 15, 2026. The inventors are Philip Richard Jackson, Mark Cresswell, and Ian F. Campbell, with the application classified under pharmaceutical formulation codes A61K 9/14, A61K 9/16, A61K 9/20, and A61K 31/00. The patent designation extends across all European Patent Convention contracting states including Germany, France, the United Kingdom, Italy, Spain, and 25 others. Pharmaceutical manufacturers developing similar porous particle formulations should evaluate freedom-to-operate implications within the designated states.

I-59 and U.S. 49 Ramp Closures, Forrest County, April 27-28

MDOT has issued a traffic advisory for temporary ramp closures at the U.S. 49 N ramp to I-59 N and the I-59 S ramp to U.S. 49 N in Forrest County. The closures are scheduled for Monday, April 27 and Tuesday, April 28, 2026, from 6:00 a.m. to 4:30 p.m. each day. The work is associated with an ongoing interstate resurfacing project, and motorists are advised to seek alternate routes and remain alert for roadside workers.

I-55 Lane and Ramp Closures Madison County April 22-23

MDOT announces temporary lane and ramp closures on I-55 southbound between Steed Rd. and I-220 in Madison County, Mississippi, from 9 p.m. Wednesday, April 22 until 6 a.m. Thursday, April 23 for overhead sign replacement. The Old Agency Rd. ramps to I-55 south and the Natchez Trace Parkway ramp to I-55 south will be temporarily closed. Motorists seeking southbound I-55 access should use I-55 north to Colony Park Blvd. or seek alternate routes.

MDOT Litter Cleanup Spring 2026 Mississippi Highways

MDOT announced its annual spring litter prevention and cleanup campaign along Mississippi state highways this April, coinciding with Earth Day (April 22) and Keep America Beautiful Month. The agency is hosting Trash Bash events across multiple Mississippi districts through late April 2026 in partnership with Keep Mississippi Beautiful as part of the national Great American Cleanup campaign, which has run annually since 1989. MDOT employees are volunteering to remove thousands of bags of trash from highly visible roadside areas and conducting litter prevention education at schools and communities statewide.

Old Byram Rd Bridge Closure, May 11 to June 22

MDOT has issued an updated traffic advisory for a temporary bridge closure on Old Byram Rd. over I-55 in Hinds County. The closure begins at 7 a.m. on Monday, May 11 and runs through Monday, June 22, 2026. Drivers should seek alternate routes during the closure and can stay updated via MDOTtraffic.com, the MDOT Traffic mobile app, or by following @MississippiDOT on Facebook and X.

Influence of Genetic Polymorphism on Dose-Dependent Analgesic Response and Safety to Propofol in General Anesthesia

This ClinicalTrials.gov entry registers a new observational study (NCT07543523) investigating how genetic polymorphisms in drug-metabolizing enzymes — CYP2B6, CYP2C9, and UGT1A9 — affect individual patient response to propofol, a widely used intravenous anesthetic. The study will enroll patients undergoing general anesthesia and assess outcomes including induction time, recovery time, and adverse-effect profiles across poor and altered metabolizer phenotypes. Study interventions include Propofol Group and Isoflurane Group assignments, with conditions focused on analgesia.

Phase 2 Brenipatide (LY3537031) Trial for IBS-D, Apr 2026

NIH's ClinicalTrials.gov has registered a new Phase 2 clinical trial (NCT07545759) evaluating subcutaneously administered brenipatide (LY3537031) against placebo in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D). The study will assess tolerability, safety, and efficacy over approximately 35 weeks. No regulatory approval, efficacy finding, or compliance obligation is established by this registry entry.

Determines Effect of Virtual Glasses on Pain and Anxiety During IUD Application

A randomized controlled experimental study registered on ClinicalTrials.gov (NCT07545850) investigates whether using virtual reality glasses during intrauterine device (IUD) application affects pain and anxiety levels in women. The study, registered as of April 22, 2026, tests two hypotheses: that VR during IUD insertion impacts pain levels (H1-a) and anxiety levels (H1-b). This is an observational healthcare research entry documenting study parameters rather than a regulatory action.

Phase 1b aKLmRNA Trial for Aging, 21 Subjects

A Phase 1b randomized, double-blind, placebo-controlled clinical trial (NCT07544420) evaluating aKLmRNA (AKL003), a novel mRNA-mediated protein replacement therapy formulated in lipid nanoparticles, will enroll approximately 21 subjects with the condition of aging. Subjects will be randomized in a 2:1 ratio (active treatment:placebo), with each receiving two injections of 0.5 mg aKLmRNA or saline placebo. The study is registered on ClinicalTrials.gov as a Phase 1 trial with an April 22, 2026 posting date.

Phase 1 DISP-10 Trial for Advanced GI Cancers

NIH registered a Phase 1 multicenter open-label study (NCT07544589) evaluating DISP-10, a combination therapy of DV-10 adenovirus and idecabtagene vicleucel (BCMA-directed CAR-T), in adult participants with advanced gastrointestinal cancers including colorectal, gastric, esophageal, and gastroesophageal adenocarcinoma. The trial consists of dose-escalation (Part 1) to establish a recommended dose for expansion, followed by dose-expansion (Part 2) to evaluate safety and efficacy at that dose.

Explanatory Factors and Predictors of Fatigue in Patients With Sjögren's Disease: A 3-month Longitudinal Study

This study registers a prospective longitudinal investigation examining fatigue predictors in patients diagnosed with Sjögren's disease over a 3-month period at Kahramanmaras Sutcu Imam University Medical Faculty Hospital. The study will collect demographic and clinical data including laboratory results, pressure pain threshold measurements using a digital algometer, and validated questionnaires assessing fatigue, disease activity, symptoms, anxiety, depression, pain catastrophizing, sleep quality, and physical activity at baseline and 3-month follow-up. This clinical trial registration does not create compliance obligations for regulated entities — it is an informational record of planned research.

Observational HPV Testing Study Before Subtotal Hysterectomy

Clinical trial NCT07545525 is an observational study registered on April 22, 2026, evaluating high-risk HPV testing in patients indicated for subtotal hysterectomy. Patients testing HPV-positive will proceed to expert colposcopy and conisation if clinically indicated at the time of hysterectomy. The study screens for cervical cancer and human papilloma virus as co-occurring conditions.

Radiologist-Integrated Finite Element Framework for Acromial Stress in Reverse Shoulder Arthroplasty (NCT07545707)

NCT07545707 is a prospective single-center observational study registered April 22, 2026, examining an approach using high-resolution CT and MRI scans combined with customized finite element modelling to analyze stress on the acromion of patients who have undergone reverse shoulder arthroplasty (RSA) surgery. The study will assess rotator cuff deficiency using Goutallier classification quantified as Cuff Deficiency Index (CDI) to calculate deltoid forces for finite element analysis. Von Mises stresses in specific acromion zones defined by Levy et al. will then be analyzed. The study focuses on patients with Rotator Cuff Injuries and Shoulder Fractures.

Effects of Cistanche Deserticola Supplementation on Anaerobic Exercise Performance and Recovery in Men

A double-blind, randomized, placebo-controlled clinical trial has been registered to evaluate whether 8 weeks of Cistanche deserticola supplementation combined with standardized anaerobic training improves exercise performance, recovery markers, and body composition in young adult men across different athletic training levels. Participants will be assigned to receive either Cistanche deserticola extract or matched placebo while completing the same supervised training protocol, with outcomes assessed via Wingate tests, jump performance, blood lactate, creatine kinase, and hormonal indicators.

CAA 2026 Provider-Based Clinic Compliance, Attestations, Medicare Reimbursement

K&L Gates LLP attorneys Limo Cherian, Andrew Ruskin, and Sarah Staples-Carlton analyze the Consolidated Appropriations Act of 2026 and its implications for provider-based departments. The article explains provider-based status, mandatory attestation requirements, and compliance steps hospitals and health systems must take to protect Medicare reimbursement. The episode provides practical guidance on navigating the new regulatory landscape for provider-based clinics.

LDH Confirms First Measles Case in Louisiana for 2026

The Louisiana Department of Health confirmed one case of measles in a pediatric resident of Region 1 (Jefferson, Orleans, Plaquemines, and St. Bernard parishes) on April 22, 2026. The patient, who was partially vaccinated and exposed during international travel, is in isolation and receiving treatment at a Region 1 hospital. Public exposures occurred at two Kenner retail locations on April 17. This is the first measles case reported in Louisiana in 2026, following three cases in 2025.

NCUA Proposes Amending Credit Union-to-Bank Merger Regulations

The NCUA Board is proposing to amend 12 CFR part 708a, subpart C to streamline merger requirements for insured credit unions converting to banks. The proposal would eliminate the definition of "clear and conspicuous" formatting requirements (currently mandating bold type and minimum 12-point font), remove the requirement to publish pre-board-vote notice in a general circulation newspaper in favor of a member home banking landing page notice, and revise due diligence reporting requirements for merger partner location and negotiation description. The Board is accepting public comments through June 22, 2026. Credit unions considering bank mergers and financial institutions advising on such transactions should monitor this rulemaking, as it could materially alter the procedural and disclosure landscape for charter conversions.

Meeting Registration List, EERE-2023-BT-STD-0005, posted 22nd Apr

EERE posted a meeting registration list for proceeding EERE-2023-BT-STD-0005 on April 22. This document identifies participants registered to attend a meeting related to building technology and efficiency standards. The registration list is an administrative record-keeping document with no compliance obligations or regulatory changes.

Miguel Vega v. Commissioner of Correction — Brady Disclosure

The Connecticut Supreme Court in Miguel Vega v. Commissioner of Correction affirmed the Appellate Court's judgment on an alternative basis, holding that while a prosecutor's duty under Brady extends to exculpatory information known to other prosecutors in the same state's attorney's office, the failure to disclose a witness's prior false testimony was immaterial because there was no reasonable probability it would have changed the outcome of Vega's murder trial. The court reversed the Appellate Court's rationale that the prosecutor had no responsibility to search unrelated case files absent a specific defense request. Argued October 29, 2025—officially released April 21, 2026.

State v. Lang — Rehearing Request Not Considered

The Louisiana Court of Appeal, First Circuit declined to consider Isiah Lang's application for rehearing, citing the court's denial of the original writ application as the basis for non-consideration. The ruling invokes Uniform Rules of Louisiana Courts of Appeal, Rules 2-18.1 and 2-18.7, which govern when rehearing applications may be entertained. The matter originated in the 19th Judicial District Court, Parish of East Baton Rouge, under docket DC-24-02369.

Thomas Abrams v. Ochsner Clinic Foundation (2) - Rehearing Denied

The Louisiana Court of Appeal, First Circuit, denied an application for rehearing in the matter of Thomas Abrams et al. versus Ochsner Clinic Foundation et al. on April 22, 2026. The application was brought by Louisiana Governor Jeff Landry, the Patient's Compensation Fund Oversight Board, and the Louisiana Division of Administration. The court's denial of rehearing affirms the prior ruling in this consolidated case involving multiple district court docket numbers.

Central Bank of Iceland Inflation Target 2.5% Interest Rate Policy

Seðlabanki Íslands (Central Bank of Iceland) publishes its monetary policy framework explaining that price stability, defined as 2.5% annual inflation, is a primary objective and the bank is required to keep inflation at or near that target on average. The principal policy instrument is the bank's key interest rate in transactions with other financial institutions. The Monetary Policy Committee (Peningastefnunefnd) sets interest rates and deploys other monetary policy tools based on assessment of economic conditions and outlook. Well-formed monetary policy promotes increased prosperity by ensuring stable prices.

Financial Stability Goals, Macroprudential Policy, and Stress Tests

Seðlabanki Íslands (Central Bank of Iceland) publishes an institutional overview page describing its financial stability mandate, the role of the Fjármálastöðugleikanefnd (Financial Stability Committee), and the macroprudential tools used to promote a stable financial system. The page summarises the semi-annual Fjármálastöðugleiki publication, annual stress testing of systemically important banks, and the Bank's resolution authority over Icelandic financial institutions. No new compliance obligations, deadlines, or penalties are created.

Financial Supervision at Central Bank of Iceland

The Central Bank of Iceland maintains ongoing financial supervision over entities classified as supervised parties under public financial supervision legislation. The Fjármálaeftirlitsnefnd (Financial Supervision Committee) sets policy on administrative sanctions and coercive measures, while the Deputy Governor for Financial Supervision prepares and implements supervisory strategy. Supervised activities span financial companies, pension markets, insurance, securities markets, virtual assets, anti-money laundering, and financial-market digital resilience.

Cross et al v. Google LLC - Federal Question Removal

Google LLC removed a civil action from Santa Clara County Superior Court (Case No. 24CV434680) to the Northern District of California on April 22, 2026. The federal case, captioned Cross et al v. Google LLC, was filed under Federal Question jurisdiction with Other Statutory Actions as the nature of suit. Google filed the Notice of Removal along with a $405 filing fee and corporate disclosure identifying XXVI Holdings Inc. and Alphabet Inc. as corporate parents.

Hoefling et al v. Google LLC - Notice of Removal, Santa Clara County Superior Court

Civil case Hoefling et al v. Google LLC filed in the Northern District of California, San Jose division, on April 22, 2026 under case number 5:26-cv-03408. Google LLC filed a Notice of Removal from Santa Clara County Superior Court (case number 24CV434676), accompanied by a $405 filing fee and corporate disclosure statement identifying XXVI Holdings Inc. and Alphabet Inc. as corporate parents.

Sturgis et al v. Google LLC - Notice of Removal from Santa Clara County Superior Court

Google LLC filed a Notice of Removal on April 22, 2026, transferring case 24CV434813 from Santa Clara County Superior Court to the Northern District of California (Case 5:26-cv-03402). The case, captioned Sturgis et al v. Google LLC, is classified as a civil action with Federal Question jurisdiction under Other Statutory Actions. Google disclosed its corporate parents as XXVI Holdings Inc. and Alphabet Inc. in Rule 7.1 disclosures.

Schaffer et al v. Google LLC - Civil Case, San Jose

Schaffer et al filed a civil action against Google LLC in the Northern District of California, San Jose Division, on April 22, 2026. The case, numbered 5:26-cv-03406, is categorized as a Federal Question with Nature of Suit listed as Other Statutory Actions. Google LLC subsequently filed a Notice of Removal on the same date, removing the case from Santa Clara County Superior Court (case number 24CV434800) to federal court, with a filing fee of $405.

Khoshaba v. Mullin et al - Immigration Case, San Francisco

Khoshaba v. Mullin et al was filed in the Northern District of California on April 22, 2026. The case is classified as a civil matter under 'Other Immigration Actions' against a U.S. Government defendant. No publicly available case summary or recent filings were identified at the time of indexing, and additional details may require access via PACER.

Mogaddedi v. Marriott International, Inc. - Civil Rights Employment Case

Civil rights employment lawsuit filed by Mogaddedi against Marriott International, Inc. in the Northern District of California. The case was removed from San Francisco County Superior Court (Case No. CGC-26-634687) to federal court by Marriott on April 22, 2026. The removal filing included three supporting declarations and corporate disclosures, with a $405 filing fee.

Huballa et al v. Google LLC

Google LLC filed a Notice of Removal on April 22, 2026, transferring Huballa et al v. Google LLC (case 24CV434807) from Santa Clara County Superior Court to the Northern District of California (5:26-cv-03409). The removal filing included a $405 filing fee and identified XXVI Holdings Inc. as the corporate parent of Google LLC. The case, categorized as a Federal Question with Other Statutory Actions, is now pending in federal court in San Jose.

Vargas et al v. Google LLC - Civil Case, San Jose

Vargas et al filed a civil case against Google LLC in the Northern District of California, San Jose division, on April 22, 2026. The docket shows two filings that same day: Google LLC's Notice of Removal from Santa Clara County Superior Court (case number 24CV434699) with a $405 filing fee, and Google's Corporate Disclosure Statement identifying Alphabet Inc. and XXVI Holdings Inc. as corporate parents.

Jones et al v. Google LLC

Jones et al filed a civil action against Google LLC in the Northern District of California on April 22, 2026, case number 5:26-cv-03401. Google LLC filed a Notice of Removal from Santa Clara County Superior Court, where the case bore number 24CV434681, along with a Corporate Disclosure Statement identifying Alphabet Inc. and XXVI Holdings Inc. as parent holding companies. The case is classified as a Federal Question with nature of suit listed as Other Statutory Actions.

Gustafson et al v. Google LLC - Notice of Removal

Gustafson et al filed a civil action against Google LLC in the Northern District of California on April 22, 2026, case number 5:26-cv-03412. Google LLC filed a Notice of Removal removing the case from Santa Clara County Superior Court (case number 24CV434810) to federal court, with a filing fee of $405. Google LLC also filed Rule 7.1 Disclosures identifying Alphabet Inc. and XXVI Holdings Inc. as corporate parents.

Cummings et al v. Google LLC – Civil Case Removed to Federal Court

Cummings et al filed a civil lawsuit against Google LLC in the Northern District of California on April 22, 2026. Google LLC subsequently filed a Notice of Removal from Santa Clara County Superior Court (case number 24CV434689), paying a $405 filing fee and submitting a Corporate Disclosure Statement identifying Alphabet Inc. and XXVI Holdings Inc. as parent holding companies. No case summary or substantive claims have been made available.

Cisco API Security Scoring, European Patent EP4205357A1

European Patent Application EP4205357A1 titled 'API Key Security Posture Scoring for Microservices to Determine Microservice Security Risks' was published on April 15, 2026. The patent application, filed by Cisco Technology, Inc., covers methods and systems for scoring API key security posture in microservices architectures to determine security risks. The designated states include all EPO member states across the European Union and related territories.

EP3902142A1 QC-LDPC Coding Patent, MediaTek, April 2026

MediaTek Inc. has been granted European Patent EP3902142A1 for QC-LDPC (Quasi-Cyclic Low-Density Parity-Check) coding methods and apparatus, published on 15 April 2026. The patent covers IPC classifications H03M 13/11, H03M 13/00, H04L 1/00, H04L 1/18, and H03M 13/03, relating to error correction coding in digital communications. Protection extends to all designated EPC contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

European Patent Application EP4115579A1: Managing Internet Site Access Request From Device

The European Patent Office published patent application EP4115579A1 on April 15, 2026, titled 'Method for Managing a Request to Access an Internet Site from an Access Device.' The application was filed by Orange with inventors BOUVET, Eric and FONTAINE, Fabrice. IPC classifications cover H04L 29/06 and H04L 29/12 relating to digital communications protocols. Designated states include all EU member states plus additional European countries. This publication makes the application publicly accessible for opposition and observation purposes.